Celcuity (CELC) Receives FDA Approval for Breakthrough Breast Cancer Treatment
Related Stocks: CELC
Read the full articleYou might also wanna read
US FDA approves Celcuity’s breast cancer drug
By Kunal Das and Christy Santhosh July 14 (Reuters) - The U.S. FDA has approved Celcuity's drug for an advanced form of breast cancer, the r
US FDA approves Celcuity’s breast cancer drug
By Kunal Das and Christy Santhosh July 14 (Reuters) - The U.S. FDA has approved Celcuity's drug for an advanced form of breast cancer, the r
With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big Pharma
The FDA has approved a new small molecule inhibitor from Celcuity with blockbuster potential that could become a new standard-of-care for pa
Celcuity Inc. (CELC) Stock: Slides 16% as FDA Clears REVTORPYK for Breast Cancer
TLDR Celcuity stock falls 16% despite FDA approval of REVTORPYK for breast cancer. FDA clears REVTORPYK as Celcuity advances targeted cancer
Celcuity gets FDA nod for first-in-class breast cancer drug
Celcuity gets FDA nod for first-in-class breast cancer drug Phil.Taylor Wed, 15/07/2026 - 09:10
Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
REVTORPYK (gedatolisib) REVTORPYK (gedatolisib) vial and box REVTORPYK is the first and only FDA-approved therapy that inhibits all class I
Comments
Sign in to join the conversation.
No comments yet. Be the first.